UGT1A1 and fatty liver disease: Transgenic mice that are homozygous for the human UGT1A1*28 (HuUGT*28) exhibit moderate hyperbilirubinemia and are protected against the development of dietary-induced hepatic steatosis via decreased serine 73 phosphorylation, an inhibitory site of the PPARα protein [31].